Tudor Investment Corp’s Heron Therapeutics HRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-110,121
Closed -$465K 2586
2022
Q3
$465K Buy
110,121
+66,115
+150% +$259K 0.01% 1455
2022
Q2
$123K Sell
44,006
-62,647
-59% -$252K ﹤0.01% 1902
2022
Q1
$610K Sell
106,653
-88,221
-45% -$646K 0.01% 1157
2021
Q4
$1.78M Buy
+194,874
New +$1.99M 0.03% 692
2021
Q2
Sell
-51,690
Closed -$838K 1730
2021
Q1
$838K Buy
+51,690
New +$921K 0.02% 921
2020
Q3
Sell
-84,039
Closed -$1.24M 1405
2020
Q2
$1.24M Buy
+84,039
New +$1.38M 0.06% 414
2018
Q1
Sell
-81,951
Closed -$1.48M 1092
2017
Q4
$1.48M Buy
81,951
+61,309
+297% +$1,000K 0.04% 244
2017
Q3
$333K Buy
20,642
+2,024
+11% +$31.7K 0.01% 792
2017
Q2
$258K Buy
18,618
+1,724
+10% +$25K 0.01% 803
2017
Q1
$253K Buy
+16,894
New +$234K 0.01% 1102
2016
Q2
Sell
-19,943
Closed -$379K 1755
2016
Q1
$379K Buy
+19,943
New +$393K 0.01% 1140
2015
Q4
Sell
-26,533
Closed -$647K 1731
2015
Q3
$647K Buy
26,533
+7,561
+40% +$252K 0.02% 614
2015
Q2
$591K Buy
+18,972
New +$357K 0.02% 673
2014
Q3
Sell
-40,800
Closed -$503K 1409
2014
Q2
$503K Buy
40,800
+15,801
+63% +$189K 0.02% 533
2014
Q1
$348K Buy
+24,999
New +$334K 0.01% 723

Other funds holding HRTX

Tudor Investment Corp's HRTX Position: Q4 2022 in Review

Tudor Investment Corp sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 110,121 shares — an estimated $465K sold.

Tudor Investment Corp first reported a position in HRTX in Q1 2014 and held it in 15 quarters. The position peaked at $1.78M in Q4 2021. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

  • Tudor Investment Corp reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Tudor Investment Corp sold 110,121 Heron Therapeutics shares in Q4 2022, an estimated $465K.
  • Tudor Investment Corp first reported a position in Heron Therapeutics in Q1 2014 and held it in 15 quarters.
  • Tudor Investment Corp's Heron Therapeutics position peaked at $1.78M in Q4 2021.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Tudor Investment Corp's 13F filing for Q4 2022, filed 14 Feb 2023.